Itragreat SB 65mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. It is effective against a wide range of pathogenic fungi by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itragreat SB is commonly prescribed for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, and onychomycosis, as well as infections caused by Candida species. The 65mg dosage form allows for precise dosing tailored to patient needs, often used in combination with other antifungal therapies or as monotherapy depending on the severity and type of infection. Itragreat SB should be administered orally with food to enhance absorption and bioavailability. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions must be carefully evaluated due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function and clinical response is recommended during therapy to ensure safety and efficacy. Itragreat SB 65mg Capsule is a valuable option in antifungal pharmacotherapy under appropriate medical supervision.